Decades of stalled progress

More than 7 million Americans have Alzheimer's, the leading cause of dementia. For decades, research made little headway due to groupthink and fraud from prominent researchers.

“More than 7 million Americans are living with the disease, which is the most common cause of dementia.”

Two new drugs show promise

The FDA approved lecanemab and donanemab, which target amyloid plaque buildup in the brain and slow cognitive decline in patients. These are considered the starting point for better treatments ahead.

“will hopefully have some effect in slowing down their cognitive decline.”

The amyloid hypothesis vindicated

Scientists long believed amyloid buildup caused Alzheimer's but had no proof for years. These new drugs finally validate that theory and open the door to more targeted treatments.

Understanding is getting more complex

Beyond amyloid, researchers now see roles for tau proteins, chronic inflammation, and vascular health in Alzheimer's development. This broader understanding is opening multiple treatment avenues.

Tau treatments in early trials

Drugs targeting tau proteins are in early safety testing stages. Preliminary results look promising, suggesting a future where multiple drugs work together like cancer treatments.

A future cocktail of treatments

Scientists hope that in five to ten years, patients will take multiple drugs targeting different disease mechanisms, similar to how cancer is treated, potentially stopping or reversing progression.

“The hope is that five, 10 years from now, we've got a much more robust suite of treatments”

GLP-1 drugs might prevent it

Drugs like semaglutide used for weight loss may reduce Alzheimer's risk by improving vascular health. The Alzheimer's Association is investing 100 million dollars to study this connection.

The vascular connection

Better blood flow and lower blood pressure from weight loss could protect the brain. This theory makes sense and explains why GLP-1 drugs might have unexpected benefits for dementia prevention.

Reversing Alzheimer's still distant

Stopping progression is the near-term goal, but scientists believe the brain's resilience means reversal may eventually be possible. Some intriguing experimental work is happening in China.

“Your brain is really resilient. It's really good at rebuilding itself if you give it the chance.”

Mysterious surgery in China

Chinese doctors performed experimental brain surgery creating a drain to remove amyloid and tau proteins. Videos show dramatic before-and-after improvements, but the findings remain unverified.

The surgery theory makes sense

The procedure creates a brain drain to help remove amyloid and tau proteins. The concept is plausible enough that scientists in the US and Europe are setting up studies to replicate the findings.

Complications and skepticism

The Chinese surgeon who pioneered the surgery was arrested on insurance fraud charges, and the government banned the procedure outside clinical trials. This has complicated the story but hasn't stopped Western researchers from investigating.

The holy grail of treatment

Restoring a patient's identity and memories is the ultimate goal. Alzheimer's uniquely robs people of who they are, making reversal the most meaningful outcome possible.

“Alzheimer's is a disease unlike any other because it robs you of your identity.”

Optimism after decades of waiting

For the first time in years, the field is genuinely hopeful. Multiple treatment approaches, new drug pipelines, and experimental breakthroughs suggest the next decade could bring transformative progress.